Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.560
-0.010 (-0.64%)
Dec 20, 2024, 4:00 PM EST - Market closed
Gain Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | - | 0.06 | 0.13 | 0.13 | - | - | Upgrade
|
| Revenue Growth (YoY) | - | -58.40% | -0.96% | - | - | - | Upgrade
|
| Cost of Revenue | 11.46 | 11.38 | 8.24 | 7.16 | 2.26 | - | Upgrade
|
| Gross Profit | -11.46 | -11.32 | -8.11 | -7.03 | -2.26 | - | Upgrade
|
| Selling, General & Admin | 9.63 | 10.93 | 9.68 | 6.84 | 1.25 | 0.56 | Upgrade
|
| Research & Development | 0.34 | - | - | - | - | 1.59 | Upgrade
|
| Other Operating Expenses | - | - | -0.01 | -0.03 | -0.03 | -0.04 | Upgrade
|
| Operating Expenses | 9.97 | 10.93 | 9.68 | 6.81 | 1.22 | 2.1 | Upgrade
|
| Operating Income | -21.43 | -22.26 | -17.79 | -13.84 | -3.48 | -2.1 | Upgrade
|
| Interest Expense | - | - | - | - | - | -0.02 | Upgrade
|
| Interest & Investment Income | 0.42 | 0.5 | 0.39 | 0.02 | 0 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.31 | -0.43 | -0.1 | -0.07 | -0.1 | -0.07 | Upgrade
|
| Pretax Income | -21.32 | -22.19 | -17.5 | -13.89 | -3.57 | -2.19 | Upgrade
|
| Income Tax Expense | 0.05 | 0.08 | 0.09 | 0 | 0.01 | 0.01 | Upgrade
|
| Net Income | -21.37 | -22.27 | -17.59 | -13.89 | -3.58 | -2.19 | Upgrade
|
| Net Income to Common | -21.37 | -22.27 | -17.59 | -13.89 | -3.58 | -2.19 | Upgrade
|
| Shares Outstanding (Basic) | 20 | 13 | 12 | 10 | 3 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 20 | 13 | 12 | 10 | 3 | 2 | Upgrade
|
| Shares Change (YoY) | 61.20% | 9.49% | 16.90% | 279.11% | 19.17% | - | Upgrade
|
| EPS (Basic) | -1.08 | -1.71 | -1.48 | -1.37 | -1.33 | -0.97 | Upgrade
|
| EPS (Diluted) | -1.08 | -1.71 | -1.48 | -1.37 | -1.33 | -0.97 | Upgrade
|
| Free Cash Flow | -21.1 | -18.88 | -14.81 | -12.46 | -3.26 | -1.88 | Upgrade
|
| Free Cash Flow Per Share | -1.07 | -1.45 | -1.25 | -1.23 | -1.22 | -0.84 | Upgrade
|
| Operating Margin | - | -40336.86% | -13410.18% | -10332.05% | - | - | Upgrade
|
| Profit Margin | - | -40354.33% | -13262.02% | -10371.70% | - | - | Upgrade
|
| Free Cash Flow Margin | - | -34217.53% | -11166.38% | -9303.42% | - | - | Upgrade
|
| EBITDA | -21.39 | -22.22 | -17.76 | -13.82 | -3.47 | -2.1 | Upgrade
|
| D&A For EBITDA | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | 0 | Upgrade
|
| EBIT | -21.43 | -22.26 | -17.79 | -13.84 | -3.48 | -2.1 | Upgrade
|
| Revenue as Reported | - | 0.06 | 0.14 | 0.16 | 0.03 | 0.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.